Cargando…

Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Can, Wang, Runlu, Chen, Xi, Hou, Yulong, Jiang, Jingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289165/
https://www.ncbi.nlm.nih.gov/pubmed/35860564
http://dx.doi.org/10.3389/fonc.2022.924740
_version_ 1784748602947534848
author Chen, Can
Wang, Runlu
Chen, Xi
Hou, Yulong
Jiang, Jingting
author_facet Chen, Can
Wang, Runlu
Chen, Xi
Hou, Yulong
Jiang, Jingting
author_sort Chen, Can
collection PubMed
description Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer.
format Online
Article
Text
id pubmed-9289165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92891652022-07-19 Targeting CD47 as a Novel Immunotherapy for Breast Cancer Chen, Can Wang, Runlu Chen, Xi Hou, Yulong Jiang, Jingting Front Oncol Oncology Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289165/ /pubmed/35860564 http://dx.doi.org/10.3389/fonc.2022.924740 Text en Copyright © 2022 Chen, Wang, Chen, Hou and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Can
Wang, Runlu
Chen, Xi
Hou, Yulong
Jiang, Jingting
Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title_full Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title_fullStr Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title_full_unstemmed Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title_short Targeting CD47 as a Novel Immunotherapy for Breast Cancer
title_sort targeting cd47 as a novel immunotherapy for breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289165/
https://www.ncbi.nlm.nih.gov/pubmed/35860564
http://dx.doi.org/10.3389/fonc.2022.924740
work_keys_str_mv AT chencan targetingcd47asanovelimmunotherapyforbreastcancer
AT wangrunlu targetingcd47asanovelimmunotherapyforbreastcancer
AT chenxi targetingcd47asanovelimmunotherapyforbreastcancer
AT houyulong targetingcd47asanovelimmunotherapyforbreastcancer
AT jiangjingting targetingcd47asanovelimmunotherapyforbreastcancer